Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $35
Portfolio Pulse from richadhand@benzinga.com
Barrington Research analyst Kevin Steinke maintains an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) but lowers the price target from $42 to $35.
June 01, 2023 | 8:17 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barrington Research maintains an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) but lowers the price target from $42 to $35.
The news of Barrington Research maintaining an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) is positive for the stock. However, the lowering of the price target from $42 to $35 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100